Tyche Wealth Partners LLC Raises Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Tyche Wealth Partners LLC raised its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 10.2% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 9,185 shares of the company’s stock after purchasing an additional 850 shares during the quarter. Tyche Wealth Partners LLC’s holdings in CRISPR Therapeutics were worth $313,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Intellectus Partners LLC lifted its stake in shares of CRISPR Therapeutics by 3.6% in the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock valued at $281,000 after purchasing an additional 250 shares during the period. Farrow Financial Inc. raised its holdings in CRISPR Therapeutics by 1.4% in the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock worth $777,000 after purchasing an additional 270 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in CRISPR Therapeutics by 7.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company’s stock valued at $215,000 after buying an additional 372 shares during the period. Horizon Kinetics Asset Management LLC boosted its holdings in shares of CRISPR Therapeutics by 4.3% during the 4th quarter. Horizon Kinetics Asset Management LLC now owns 10,682 shares of the company’s stock valued at $420,000 after buying an additional 443 shares in the last quarter. Finally, First Horizon Advisors Inc. grew its position in shares of CRISPR Therapeutics by 33.4% in the 4th quarter. First Horizon Advisors Inc. now owns 2,039 shares of the company’s stock worth $80,000 after buying an additional 511 shares during the period. Institutional investors own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,932 shares of the stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total transaction of $141,316.08. Following the transaction, the insider now directly owns 6,068 shares of the company’s stock, valued at $218,083.92. This represents a 39.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Price Performance

CRSP stock opened at $47.66 on Thursday. The stock has a market capitalization of $4.12 billion, a P/E ratio of -10.54 and a beta of 1.75. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $63.68. The business has a fifty day moving average price of $39.10 and a 200-day moving average price of $40.58.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. The company’s revenue for the quarter was up 71.6% on a year-over-year basis. During the same period in the prior year, the company earned ($1.43) earnings per share. As a group, analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

CRSP has been the subject of a number of recent research reports. Wall Street Zen raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Friday, May 16th. Barclays lowered their target price on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating for the company in a report on Friday, May 9th. Chardan Capital cut their price target on CRISPR Therapeutics from $84.00 to $82.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $81.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, May 20th. Finally, The Goldman Sachs Group dropped their target price on CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating on the stock in a report on Thursday, May 8th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and an average price target of $69.53.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.